1
|
Hollingshead BD, Khan N, Schuler M, Radi Z. Development challenges for carcinogenicity risk assessments of topical drugs. J Toxicol Sci 2022; 47:1-11. [PMID: 34987136 DOI: 10.2131/jts.47.1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
The nonclinical safety package to support development and approval of drugs intended to be administered by topical application generally follows International Council for Harmonisation multidisciplinary 3 (ICH M3) and topic specific safety (ICH S) guidances. However, some aspects of topical drug development may require case-by-case determination of nonclinical safety strategies. The necessity to conduct a dermal rodent carcinogenicity study is one such example that is not considered an obligate component of a nonclinical safety data package for drug approval. While absence of systemic exposure, as stated in ICH M3, is a primary reason to forego a dermal carcinogenicity assessment, there may also be other factors for consideration in determining the need for a life-time carcinogencity study by dermal route to aid in the overall human cancer risk assessment. We therefore reviewed nonclinical carcinogencity data packages from drugs approved by the FDA or PMDA over a ~25 year time period to evaluate outcomes of oral versus topical carcinogencity studies and to understand their utility for informing the overall human risk assessment. We also discuss various other properties of topical small molecules that could impact the decisions to conduct a dermal life-time rodent carcinogenicity study. Collectively, the need to conduct 2-year dermal carcinogenicity studies in rodents should be determined case-by-case and consider scientific factors such existing systemic toxicity and carcinogenicity study data, anticipated drug exposures in skin, skin evaluation from the chronic minipig toxicity study, and genetic toxicity profile.
Collapse
Affiliation(s)
- Brett D Hollingshead
- Pfizer Drug Safety Research and Development, 1 Portland Street Cambridge, MA, USA
| | - Nasir Khan
- Pfizer Drug Safety Research and Development, 445 Eastern Point Road, Groton, CT, USA
| | - Maik Schuler
- Pfizer Drug Safety Research and Development, 445 Eastern Point Road, Groton, CT, USA
| | - Zaher Radi
- Pfizer Drug Safety Research and Development, 1 Portland Street Cambridge, MA, USA
| |
Collapse
|
2
|
Hollingshead BD, Tomlinson L, Finley J, Doshna C, Ritenour C, Barricklow J, Oppenheimer SR, O'Neil SP, Moore JL, Patterson NH, Nicholson SP, Norris JL, Caprioli RM, Beaumont K, King-Ahmad AJ, Vispute S, Cook JC, Radi Z, Schuler M. An orthogonal methods assessment of topical drug concentrations in skin and the impact for risk assessment in the viable epidermis. Regul Toxicol Pharmacol 2021; 123:104934. [PMID: 33872740 DOI: 10.1016/j.yrtph.2021.104934] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2021] [Revised: 03/15/2021] [Accepted: 04/12/2021] [Indexed: 11/30/2022]
Abstract
Systemic toxicity assessments for oral or parenteral drugs often utilize the concentration of drug in plasma to enable safety margin calculations for human risk assessment. For topical drugs, there is no standard method for measuring drug concentrations in the stratum basale of the viable epidermis. This is particularly important since the superficial part of the epidermis, the stratum corneum (SC), is nonviable and where most of a topically applied drug remains, never penetrating deeper into the skin. We investigated the relative concentrations of a prototype kinase inhibitor using punch biopsy, laser capture microdissection, and imaging mass spectrometry methods in the SC, stratum basale, and dermis of minipig skin following topical application as a cream formulation. The results highlight the value of laser capture microdissection and mass spectrometry imaging in quantifying the large difference in drug concentration across the skin and even within the epidermis, and supports use of these methods for threshold-based toxicity risk assessments in specific anatomic locations of the skin, like of the stratum basale.
Collapse
Affiliation(s)
- Brett D Hollingshead
- Pfizer Drug Safety Research and Development, 1 Portland Street, Cambridge, MA, 02139, USA.
| | - Lindsay Tomlinson
- Pfizer Drug Safety Research and Development, 1 Portland Street, Cambridge, MA, 02139, USA
| | - Jim Finley
- Pfizer Drug Safety Research and Development, Eastern Point Road, Groton, CT, 06340, USA
| | - Colleen Doshna
- Pfizer Drug Safety Research and Development, Eastern Point Road, Groton, CT, 06340, USA
| | - Casey Ritenour
- Pfizer Drug Safety Research and Development, Eastern Point Road, Groton, CT, 06340, USA
| | - Jason Barricklow
- Pfizer Pharmacokinetics, Dynamics and Metabolism, Eastern Point Road, Groton, CT, 06340, USA
| | | | - Shawn P O'Neil
- Pfizer Drug Safety Research and Development, 1 Portland Street, Cambridge, MA, 02139, USA
| | - Jessica L Moore
- Frontier Diagnostics, 345 Hill Ave, Nashville, TN, 37210, USA
| | | | | | - Jeremy L Norris
- Frontier Diagnostics, 345 Hill Ave, Nashville, TN, 37210, USA
| | | | - Kevin Beaumont
- Pfizer Pharmacokinetics, Dynamics and Metabolism, 1 Portland Street, Cambridge, MA, 02139, USA
| | - Amanda J King-Ahmad
- Pfizer Pharmacokinetics, Dynamics and Metabolism, Eastern Point Road, Groton, CT, 06340, USA
| | - Saurabh Vispute
- Pfizer Drug Safety Research and Development, Eastern Point Road, Groton, CT, 06340, USA
| | - Jon C Cook
- Pfizer Drug Safety Research and Development, Eastern Point Road, Groton, CT, 06340, USA
| | - Zaher Radi
- Pfizer Drug Safety Research and Development, 1 Portland Street, Cambridge, MA, 02139, USA
| | - Maik Schuler
- Pfizer Drug Safety Research and Development, Eastern Point Road, Groton, CT, 06340, USA
| |
Collapse
|
3
|
Development, characterization and evaluation of nanocarrier based formulations of antipsoriatic drug “acitretin” for skin targeting. J Drug Deliv Sci Technol 2020. [DOI: 10.1016/j.jddst.2020.102010] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
4
|
Berstein G, Zhang Y, Berger Z, Kieras E, Li G, Samuel A, Yeoh T, Dowty H, Beaumont K, Wigger-Alberti W, von Mackensen Y, Kroencke U, Hamscho R, Garcet S, Krueger JG, Banfield C, Oemar B. A phase I, randomized, double-blind study to assess the safety, tolerability and efficacy of the topical RORC2 inverse agonist PF-06763809 in participants with mild-to-moderate plaque psoriasis. Clin Exp Dermatol 2020; 46:122-129. [PMID: 32767679 PMCID: PMC7756278 DOI: 10.1111/ced.14412] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2020] [Revised: 07/27/2020] [Accepted: 08/04/2020] [Indexed: 11/27/2022]
Abstract
BACKGROUND Transcription factor retinoic acid-related orphan receptor 2 (RORC2/RORγT) mediates interleukin (IL)-17A and IL-17F expression. IL-17A plays a central role in the pathogenesis of several inflammatory disorders, including psoriasis. The RORC2 inhibitor PF-06763809 has been hypothesized to inhibit IL-17A production in T-helper 17 (Th17) cells, thereby reducing psoriasis symptoms. AIM To assess the safety, tolerability and effect on skin infiltrate thickness of PF-06763809 in participants with mild/moderate chronic plaque psoriasis. METHODS This was a randomized, double-blind, first-in-human study (trial registration: ClinicalTrials.gov NCT03469336). Participants received each of the following six treatments once daily for 18 days: three topical doses (2.3%, 0.8%, 0.23%) of PF-06763809, a vehicle and two active comparators (betamethasone and calcipotriol). Primary endpoints included change from baseline in psoriatic skin infiltrate thickness [echo-poor band (EPB) on ultrasonography] at Day 19, and safety. Change in psoriasis-associated gene expression (Day 19), evaluated by real-time reverse transcription PCR of skin biopsies, was an exploratory endpoint. RESULTS In total, 17 participants completed the study. Change from baseline in the EPB on Day 19 for all three doses of PF-06763809 was not significantly different from that of vehicle (P > 0.05). A significant reduction in EPB from baseline was observed with betamethasone on Day 19 relative to all other treatments (P < 0.0001). Treatment-related adverse events were mild/moderate. There were no significant differences in gene expression on Day 19 between vehicle and PF-06763809-treated skin lesions. CONCLUSION Using a psoriasis plaque test design, PF-06763809 was found to be well tolerated with an acceptable safety profile in participants with psoriasis, but without reduction in skin infiltrate thickness or disease biomarkers.
Collapse
Affiliation(s)
- G Berstein
- Inflammation and Immunology Research Unit, Pfizer Inc., Cambridge, MA, USA
| | - Y Zhang
- Inflammation and Immunology Research Unit, Pfizer Inc., Cambridge, MA, USA
| | - Z Berger
- Inflammation and Immunology Research Unit, Pfizer Inc., Cambridge, MA, USA
| | - E Kieras
- Inflammation and Immunology Research Unit, Pfizer Inc., Cambridge, MA, USA
| | - G Li
- Early Clinical Development, Pfizer Inc., Collegeville, PA, USA
| | - A Samuel
- Formulation and Process Design, Pfizer Inc., Groton, CT, USA
| | - T Yeoh
- Formulation and Process Design, Pfizer Inc., Groton, CT, USA
| | - H Dowty
- Inflammation and Immunology Research Unit, Pfizer Inc., Cambridge, MA, USA
| | - K Beaumont
- Inflammation and Immunology Research Unit, Pfizer Inc., Cambridge, MA, USA
| | | | | | | | - R Hamscho
- Rothhaar Studien GmbH, Berlin, Germany
| | - S Garcet
- Rockefeller University, New York, NY, USA
| | | | - C Banfield
- Inflammation and Immunology Research Unit, Pfizer Inc., Cambridge, MA, USA
| | - B Oemar
- Inflammation and Immunology Research Unit, Pfizer Inc., Cambridge, MA, USA
| |
Collapse
|
5
|
Mohd Ariffin NH, Hasham R. Assessment of non-invasive techniques and herbal-based products on dermatological physiology and intercellular lipid properties. Heliyon 2020; 6:e03955. [PMID: 32478187 PMCID: PMC7251381 DOI: 10.1016/j.heliyon.2020.e03955] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2019] [Revised: 10/07/2019] [Accepted: 05/04/2020] [Indexed: 01/12/2023] Open
Abstract
Skin is the largest external organ of the human body. It acts as a barrier to protect the human body from environmental pollution, mechanical stress, and excessive water loss. The defensive function resides primarily on top of the epidermis layer commonly known as stratum corneum (SC). Human SC consists of three major lipids, namely ceramide, free fatty acid, and cholesterol that comprise approximately 50%, 25%, and 25% of the total lipid mass, respectively. The optimal composition of SC lipids is the vital epidermal barrier function of the skin. On the other hand, skin barrier serves to limit passive water loss from the body, reduces chemical absorption from the environment, and prevents microbial infection. In contrast, epidermal lipids are important to maintain the cell structure, growth and differentiation, cohesion and desquamation as well as formation of a permeability barrier. Multiple non-invasive in vivo approaches were implemented on a regular basis to monitor skin physiological and intercellular lipid properties. The measurement of different parameters such as transepidermal water loss (TEWL), hydration level, skin elasticity, collagen intensity, melanin content, sebum, pH, and tape stripping is essential to evaluate the epidermal barrier function. Novel non-invasive techniques such as tape stripping, ultrasound imaging, and laser confocal microscopy offer higher possibility of accurate and detailed characterisation of skin barrier. To date, these techniques have also been widely used to determine the effects of herbal plants in dermatology. Herbal plants have been traditionally used for ages to treat a variety of skin diseases, as reported by the World Health Organisation (WHO). Their availability, lower cost, and minimal or no side effects have created awareness among society, thus increase the demand for natural sources as the remedy to treat various skin diseases. This paper reviews several non-invasive techniques and evaluations of herbal-based product in dermatology.
Collapse
Affiliation(s)
- Nor Hazwani Mohd Ariffin
- Institute of Bioproduct Development, Universiti Teknologi Malaysia, 81310 Johor Bahru, Johor, Malaysia
- Department of Bioprocess and Polymer Engineering, School of Chemical and Energy Engineering, Faculty of Engineering, Universiti Teknologi Malaysia, 81310 Johor Bahru, Johor, Malaysia
| | - Rosnani Hasham
- Institute of Bioproduct Development, Universiti Teknologi Malaysia, 81310 Johor Bahru, Johor, Malaysia
- Department of Bioprocess and Polymer Engineering, School of Chemical and Energy Engineering, Faculty of Engineering, Universiti Teknologi Malaysia, 81310 Johor Bahru, Johor, Malaysia
| |
Collapse
|
6
|
Fundamentals of fractional laser-assisted drug delivery: An in-depth guide to experimental methodology and data interpretation. Adv Drug Deliv Rev 2020; 153:169-184. [PMID: 31628965 DOI: 10.1016/j.addr.2019.10.003] [Citation(s) in RCA: 53] [Impact Index Per Article: 13.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2019] [Revised: 10/07/2019] [Accepted: 10/15/2019] [Indexed: 01/23/2023]
Abstract
In the decade since their advent, ablative fractional lasers have emerged as powerful tools to enhance drug delivery to and through the skin. Effective and highly customizable, laser-assisted drug delivery (LADD) has led to improved therapeutic outcomes for several medical indications. However, for LADD to reach maturity as a standard treatment technique, a greater appreciation of its underlying science is needed. This work aims to provide an in-depth guide to the technology's fundamental principles, experimental methodology and unique aspects of LADD data interpretation. We show that drug's physicochemical properties including solubility, molecular weight and tissue binding behavior, are crucial determinants of how laser channel morphology influences topical delivery. Furthermore, we identify strengths and limitations of experimental models and drug detection techniques, interrogating the usefulness of in vitro data in predicting LADD in vivo. By compiling insights from over 75 studies, we ultimately devise an approach for intelligent application of LADD, supporting its implementation in the clinical setting.
Collapse
|
7
|
Abu Hashim II, Abo El-Magd NF, El-Sheakh AR, Hamed MF, Abd El-Gawad AEGH. Pivotal role of Acitretin nanovesicular gel for effective treatment of psoriasis: ex vivo-in vivo evaluation study. Int J Nanomedicine 2018; 13:1059-1079. [PMID: 29503541 PMCID: PMC5824759 DOI: 10.2147/ijn.s156412] [Citation(s) in RCA: 53] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
The goal of the current study was to explore the potential benefits of Acitretin (Act) nanovesicular gel as a prospective antipsoriatic topical delivery system counteracting the drug challenges in terms of its extremely low aqueous solubility, instability, skin irritation, and serious systemic adverse effects. Act-loaded niosomes were successfully developed, entirely characterized, and optimized. Further evaluation of the optimized formula was conducted regarding its stability and ex vivo cytotoxicity on different cell lines. The optimized niosomal vesicles were then incorporated in gel base matrix and investigated by sequential ex vivo (skin permeation and deposition) and in vivo (skin irritation and antipsoriatic activity using mouse tail model) experiments. The optimized Act-loaded niosomes (span 60:cholesterol molar ratio 1:1) were spherical in shape and exhibited the highest entrapment efficiency (90.32±3.80%) with appropriate nanosize and zeta potential of 369.73±45.45 nm and -36.33±1.80 mV, respectively. Encapsulation of the drug in the nanovesicles was further emphasized by differential scanning calorimetric and powder X-ray diffraction studies. After 3 months storage at 4±1°C, the optimized formula preserved its stability. Act nano niosomal gel produced a remarkable enhanced ex vivo permeation profile up to 30 h and significant drug deposition in the viable epidermal-dermal layers compared with those of Act gel. The pronounced antipsoriatic activity of the medicated nano niosomes was proved ex vivo in HaCaT cells (a keratinocyte cell line). Topical application of Act nano niosomal gel to mouse tail model further established its distinct in vivo antipsoriatic superiority in terms of significantly higher orthokeratosis, drug activity, and reduction in epidermal thickness compared with the control and other gel formulations. Also, negligible skin irritation and better skin tolerability of Act nanovesicular gel were revealed by primary irritation index and histopathologic examination.
Collapse
Affiliation(s)
| | | | - Ahmed Ramadan El-Sheakh
- Department of Pharmacology and Toxicology, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt
| | - Mohammed Fawzy Hamed
- Department of Pathology, Faculty of Veterinary Medicine, Mansoura University, Mansoura, Egypt
| | | |
Collapse
|
8
|
Erdő F, Hashimoto N, Karvaly G, Nakamichi N, Kato Y. Critical evaluation and methodological positioning of the transdermal microdialysis technique. A review. J Control Release 2016; 233:147-61. [DOI: 10.1016/j.jconrel.2016.05.035] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2016] [Revised: 05/10/2016] [Accepted: 05/13/2016] [Indexed: 01/28/2023]
|
9
|
Divya G, Panonnummal R, Gupta S, Jayakumar R, Sabitha M. Acitretin and aloe-emodin loaded chitin nanogel for the treatment of psoriasis. Eur J Pharm Biopharm 2016; 107:97-109. [PMID: 27368748 DOI: 10.1016/j.ejpb.2016.06.019] [Citation(s) in RCA: 60] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2016] [Revised: 06/14/2016] [Accepted: 06/24/2016] [Indexed: 12/20/2022]
Abstract
The present study focuses on the development of an effective topical nanogel formulation of two anti-psoriatic drugs; Acitretin (Act) and Aloe-emodin (AE) using natural polymer chitin. Simple regeneration chemistry was used to prepare Chitin Nanogel Systems (CNGs). The developed control chitin (CNGs) nanogels, acitretin loaded chitin nanogels (ActCNGs) and aloe-emodin loaded chitin nanogels (AECNGs) were characterized by DLS, SEM, FTIR, XRD and TG-DTA. The systems were found to be spherical in shape with a size range of 98±10, 138±8 and 238±6nm having zeta potential values of +28±3, +27±3 and +25±6mV for CNGs, ActCNGs and AECNGs respectively. The in vitro haemolysis assay revealed that all the nanogel systems are blood compatible. The systems exhibited higher swelling and release at acidic pH. The ex vivo skin permeation studies using porcine skin confirmed the higher deposition of the systems at epidermal and dermal layers, which was confirmed further by fluorescent imaging. The in vivo anti-psoriatic activity study using Perry's mouse tail model and skin safety studies confirmed the potential benefit of the system for topical delivery of acitretin and aloe-emodin in psoriasis.
Collapse
Affiliation(s)
- G Divya
- Amrita School of Pharmacy, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa Vidyapeetham, Amrita University, Kochi 682041, India
| | - Rajitha Panonnummal
- Amrita School of Pharmacy, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa Vidyapeetham, Amrita University, Kochi 682041, India
| | - Swati Gupta
- Amrita School of Pharmacy, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa Vidyapeetham, Amrita University, Kochi 682041, India
| | - R Jayakumar
- Amrita Centre for Nanosciences and Molecular Medicine, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa Vidyapeetham, Amrita University, Kochi 682041, India
| | - M Sabitha
- Amrita School of Pharmacy, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa Vidyapeetham, Amrita University, Kochi 682041, India.
| |
Collapse
|
10
|
Kinetics of Clobetasol-17-Propionate in Psoriatic Lesional and Non-Lesional Skin Assessed by Dermal Open Flow Microperfusion with Time and Space Resolution. Pharm Res 2016; 33:2229-38. [PMID: 27271272 PMCID: PMC4967091 DOI: 10.1007/s11095-016-1960-y] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2016] [Accepted: 05/27/2016] [Indexed: 01/28/2023]
Abstract
Purpose To evaluate the kinetics of topically applied clobetasol-17-propionate (CP-17) in lesional and non-lesional psoriatic skin when released from a commercially available low-strength cream using in vivo dermal open-flow microperfusion (dOFM). Methods Twelve patients received Dermovate® cream (CP-17, 0.05%) on small lesional and non-lesional skin test sites for 14 days, once daily. On day 1 and 14, dOFM samples were continuously taken in the dermis for 24 h post-dose and analyzed by LC-MS/MS. Probe depths were assessed by 50 MHz ultrasound scanning. Results Mixed-effects modelling identified skin condition, treatment duration and probe-depth as kinetics determining variables. The time- and depth-resolved intradermal data revealed (i) slower penetration of CP-17 into lesional than into non-lesional skin, (ii) normalized (faster) skin penetration after repeated dosing, and (iii) no CP-17 accumulation within the dermis independently of the skin condition. Conclusions Intradermal investigation of a highly lipophilic drug released from low-strength cream was successfully performed by using dOFM and timely and spatially, i.e., probe-depth dependent, resolved kinetic data were delivered. These data support the assumption that the thickened psoriatic stratum corneum might act as trap compartment which lowers the skin penetration rate for lipophilic topical drugs. Electronic supplementary material The online version of this article (doi:10.1007/s11095-016-1960-y) contains supplementary material, which is available to authorized users.
Collapse
|
11
|
Kijima S, Todo H, Matsumoto Y, Masaki R, Kadhum WR, Sugibayashi K. A useful technique using imaging mass spectrometry for detecting the skin distribution of topically applied lidocaine. J Drug Deliv Sci Technol 2016. [DOI: 10.1016/j.jddst.2016.04.004] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
12
|
Hatanaka T, Yoshida S, Kadhum WR, Todo H, Sugibayashi K. In Silico Estimation of Skin Concentration Following the Dermal Exposure to Chemicals. Pharm Res 2015. [PMID: 26195007 DOI: 10.1007/s11095-015-1756-5] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
PURPOSE To develop an in silico method based on Fick's law of diffusion to estimate the skin concentration following dermal exposure to chemicals with a wide range of lipophilicity. METHODS Permeation experiments of various chemicals were performed through rat and porcine skin. Permeation parameters, namely, permeability coefficient and partition coefficient, were obtained by the fitting of data to two-layered and one-layered diffusion models for whole and stripped skin. The mean skin concentration of chemicals during steady-state permeation was calculated using the permeation parameters and compared with the observed values. RESULTS All permeation profiles could be described by the diffusion models. The estimated skin concentrations of chemicals using permeation parameters were close to the observed levels and most data fell within the 95% confidence interval for complete prediction. The permeability coefficient and partition coefficient for stripped skin were almost constant, being independent of the permeant's lipophilicity. CONCLUSIONS Skin concentration following dermal exposure to various chemicals can be accurately estimated based on Fick's law of diffusion. This method should become a useful tool to assess the efficacy of topically applied drugs and cosmetic ingredients, as well as the risk of chemicals likely to cause skin disorders and diseases.
Collapse
Affiliation(s)
- Tomomi Hatanaka
- Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan.
| | - Shun Yoshida
- Faculty of Pharmaceutical Sciences, Josai University, 1-1 Keyakidai, Sakado, Saitama, 350-0295, Japan
| | - Wesam R Kadhum
- Faculty of Pharmaceutical Sciences, Josai University, 1-1 Keyakidai, Sakado, Saitama, 350-0295, Japan
| | - Hiroaki Todo
- Faculty of Pharmaceutical Sciences, Josai University, 1-1 Keyakidai, Sakado, Saitama, 350-0295, Japan
| | - Kenji Sugibayashi
- Faculty of Pharmaceutical Sciences, Josai University, 1-1 Keyakidai, Sakado, Saitama, 350-0295, Japan.
| |
Collapse
|
13
|
Mitra A, Leyes A, Manser K, Roadcap B, Mestre C, Tatosian D, Jin L, Uemura N. Use of minipig skin biopsy model as an innovative tool to design topical formulation to achieve desired pharmacokinetics in humans. J Pharm Sci 2015; 104:1701-8. [PMID: 25691117 DOI: 10.1002/jps.24383] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2014] [Revised: 01/14/2015] [Accepted: 01/20/2015] [Indexed: 01/06/2023]
Abstract
In vitro cadaver skin permeation studies are often conducted to characterize the permeation profile of compounds for dermal delivery. However, its utility could be limited in the case of topical products because of lack of reliable prediction of in vivo skin kinetics. In this paper, the use of in vivo skin biopsy data to guide topical formulation development is described. A formulation was developed by compounding MK-0873, a phosphodiesterase 4 (PDE4) inhibitor, into a commercially available cream base. The cream was characterized by skin pharmacokinetic studies in minipigs, which demonstrated that MK-0873 concentrations in the epidermis and dermis were substantially higher than the IC80 for human whole blood PDE4 inhibition of ∼200 nM, suggesting that cream should provide sufficient skin exposure to assess clinical efficacy. In toxicological studies, after 1 month repeat application in minipigs minor dermal irritation and minimal systemic exposure were observed. Based on these preclinical data, the cream formulation was chosen for single rising dose clinical studies, where plasma levels of MK-0873 were mostly below the LOQ, whereas skin biopsy concentrations ranged from 6.5 to 25.1 μM. These data suggested that minipig skin biopsy model can be a valuable tool to assess performance of topical formulations and guide formulation development.
Collapse
Affiliation(s)
- Amitava Mitra
- Pharmaceutical Sciences and Clinical Supply, Merck & Co. Inc
| | | | | | | | | | | | | | | |
Collapse
|
14
|
Estimation of skin concentrations of topically applied lidocaine at each depth profile. Int J Pharm 2014; 475:292-7. [DOI: 10.1016/j.ijpharm.2014.08.046] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2014] [Revised: 07/25/2014] [Accepted: 08/21/2014] [Indexed: 11/16/2022]
|
15
|
Todo H, Oshizaka T, Kadhum WR, Sugibayashi K. Mathematical model to predict skin concentration after topical application of drugs. Pharmaceutics 2013; 5:634-51. [PMID: 24351574 PMCID: PMC3873684 DOI: 10.3390/pharmaceutics5040634] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2013] [Revised: 12/07/2013] [Accepted: 12/10/2013] [Indexed: 11/16/2022] Open
Abstract
Skin permeation experiments have been broadly done since 1970s to 1980s as an evaluation method for transdermal drug delivery systems. In topically applied drug and cosmetic formulations, skin concentration of chemical compounds is more important than their skin permeations, because primary target site of the chemical compounds is skin surface or skin tissues. Furthermore, the direct pharmacological reaction of a metabolically stable drug that binds with specific receptors of known expression levels in an organ can be determined by Hill's equation. Nevertheless, little investigation was carried out on the test method of skin concentration after topically application of chemical compounds. Recently we investigated an estimating method of skin concentration of the chemical compounds from their skin permeation profiles. In the study, we took care of "3Rs" issues for animal experiments. We have proposed an equation which was capable to estimate animal skin concentration from permeation profile through the artificial membrane (silicone membrane) and animal skin. This new approach may allow the skin concentration of a drug to be predicted using Fick's second law of diffusion. The silicone membrane was found to be useful as an alternative membrane to animal skin for predicting skin concentration of chemical compounds, because an extremely excellent extrapolation to animal skin concentration was attained by calculation using the silicone membrane permeation data. In this chapter, we aimed to establish an accurate and convenient method for predicting the concentration profiles of drugs in the skin based on the skin permeation parameters of topically active drugs derived from steady-state skin permeation experiments.
Collapse
Affiliation(s)
| | | | | | - Kenji Sugibayashi
- Faculty of Pharmaceutical Sciences, Josai University, 1-1 Keyakidai, Sakado, Saitama 350-0295, Japan.
| |
Collapse
|
16
|
Surber C, Elsner P, Singh J. Howard I. Maibach: Extraordinary Leadership in Integrating Key Concepts Underpinning Our Understanding of Percutaneous Absorption and Occupational Dermatology. Skin Pharmacol Physiol 2013; 26:190-8. [DOI: 10.1159/000353622] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
The purpose of the present article is to briefly highlight some contributions of Prof. Howard I. Maibach to the field of dermatology. After a few introducing remarks regarding Howard's personal career, the article specifically reviews contributions to the understanding of percutaneous absorption and to occupational dermatology. He and his companions/coworkers established and introduced experimental prerequisites to better study and understand percutaneous absorption - both in vitro and in vivo. Not less influential was his contribution to occupational dermatology acting as a founding member of the International Contact Dermatitis Research Group and coinaugurating the North American Contact Dermatitis Group. These groups have been very active ever since. As an academic teacher, he inspired young colleagues to perform original research work and to establish their own working groups. He has done this most successfully with many fellows who worked with him over the years, and who are now leading departments or companies dedicated to dermatological research all over the world. Probably this is his most important and lasting achievement.
Collapse
|
17
|
Bodenlenz M, Höfferer C, Magnes C, Schaller-Ammann R, Schaupp L, Feichtner F, Ratzer M, Pickl K, Sinner F, Wutte A, Korsatko S, Köhler G, Legat FJ, Benfeldt EM, Wright AM, Neddermann D, Jung T, Pieber TR. Dermal PK/PD of a lipophilic topical drug in psoriatic patients by continuous intradermal membrane-free sampling. Eur J Pharm Biopharm 2012; 81:635-41. [DOI: 10.1016/j.ejpb.2012.04.009] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2011] [Revised: 03/19/2012] [Accepted: 04/16/2012] [Indexed: 11/29/2022]
|
18
|
Bioequivalence for Topical Products—An Update. Pharm Res 2010; 27:2590-601. [DOI: 10.1007/s11095-010-0250-3] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2010] [Accepted: 08/16/2010] [Indexed: 01/30/2023]
|
19
|
|
20
|
Herkenne C, Alberti I, Naik A, Kalia YN, Mathy FX, Préat V, Guy RH. In vivo methods for the assessment of topical drug bioavailability. Pharm Res 2008; 25:87-103. [PMID: 17985216 PMCID: PMC2217624 DOI: 10.1007/s11095-007-9429-7] [Citation(s) in RCA: 161] [Impact Index Per Article: 10.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2007] [Accepted: 07/24/2007] [Indexed: 11/26/2022]
Abstract
This paper reviews some current methods for the in vivo assessment of local cutaneous bioavailability in humans after topical drug application. After an introduction discussing the importance of local drug bioavailability assessment and the limitations of model-based predictions, the focus turns to the relevance of experimental studies. The available techniques are then reviewed in detail, with particular emphasis on the tape stripping and microdialysis methodologies. Other less developed techniques, including the skin biopsy, suction blister, follicle removal and confocal Raman spectroscopy techniques are also described.
Collapse
Affiliation(s)
- Christophe Herkenne
- School of Pharmaceutical Sciences, University of Geneva, 30 quai E. Ansermet, CH-1211 Geneva 4, Switzerland
- Debio Recherche Pharmaceutique S.A., Route du Levant 146, CH-1920 Martigny, Switzerland
| | - Ingo Alberti
- School of Pharmaceutical Sciences, University of Geneva, 30 quai E. Ansermet, CH-1211 Geneva 4, Switzerland
- Antares Pharma AG, Gewerbestrasse 18, 4123 Allschwil, Switzerland
| | - Aarti Naik
- School of Pharmaceutical Sciences, University of Geneva, 30 quai E. Ansermet, CH-1211 Geneva 4, Switzerland
| | - Yogeshvar N. Kalia
- School of Pharmaceutical Sciences, University of Geneva, 30 quai E. Ansermet, CH-1211 Geneva 4, Switzerland
| | - François-Xavier Mathy
- Université catholique de Louvain, Unité de pharmacie galénique, industrielle et officinale, Avenue E. Mounier 73, 1200 Brussels, Belgium
- UCB SA, Chemin du Foriest 1, 1420 Braine-l’Alleud, Belgium
| | - Véronique Préat
- Université catholique de Louvain, Unité de pharmacie galénique, industrielle et officinale, Avenue E. Mounier 73, 1200 Brussels, Belgium
| | - Richard H. Guy
- School of Pharmaceutical Sciences, University of Geneva, 30 quai E. Ansermet, CH-1211 Geneva 4, Switzerland
- Department of Pharmacy & Pharmacology, University of Bath, Claverton Down, Bath, BA2 7AY Allschwil, UK
| |
Collapse
|
21
|
Shaikh S, Birdi A, Qutubuddin S, Lakatosh E, Baskaran H. Controlled release in transdermal pressure sensitive adhesives using organosilicate nanocomposites. Ann Biomed Eng 2007; 35:2130-7. [PMID: 17786555 PMCID: PMC2811091 DOI: 10.1007/s10439-007-9369-8] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2007] [Accepted: 08/08/2007] [Indexed: 11/27/2022]
Abstract
Polydimethyl siloxane (PDMS) based pressure sensitive adhesives (PSA) incorporating organo-clays at different loadings were fabricated via solution casting. Partially exfoliated nanocomposites were obtained for the hydroxyl terminated PDMS in ethyl acetate solvent as determined by X-ray diffraction and atomic force microscopy. Drug release studies showed that the initial burst release was substantially reduced and the drug release could be controlled by the addition of organo-clay. Shear strength and shear adhesion failure temperature (SAFT) measurements indicated substantial improvement in adhesive properties of the PSA nanocomposite adhesives. Shear strength showed more than 200% improvement at the lower clay loadings and the SAFT increased by about 21% due to the reinforcement provided by the nano-dispersed clay platelets. It was found that by optimizing the level of the organosilicate additive to the polymer matrix, superior control over drug release kinetics and simultaneous improvements in adhesive properties could be attained for a transdermal PSA formulation.
Collapse
Affiliation(s)
- Sohel Shaikh
- Department of Chemical Engineering, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106-7217
| | - Anil Birdi
- Department of Biomedical Engineering, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106-7217
| | - Syed Qutubuddin
- Department of Chemical Engineering, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106-7217
| | - Eric Lakatosh
- Avery Dennison Specialty Tape Division, 7100 Lindsay Dr, Mentor, OH 44060
| | - Harihara Baskaran
- Department of Chemical Engineering, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106-7217
- Department of Biomedical Engineering, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106-7217
- Corresponding Author: Harihara Baskaran, Assistant Professor of Engineering, Case Western Reserve University, 111C, A.W. Smith Building, Cleveland, OH 44106-7217, Tel: 1-216-368-1029, Fax: 1-216-368-3016,
| |
Collapse
|
22
|
Hsia E, Johnston MJ, Houlden RJ, Chern WH, Hofland HEJ. Effects of topically applied acitretin in reconstructed human epidermis and the rhino mouse. J Invest Dermatol 2007; 128:125-30. [PMID: 17637822 DOI: 10.1038/sj.jid.5700968] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Oral acitretin is currently indicated for the treatment of severe psoriasis in adults, but its use is limited by systemic side effects and teratogenicity. Topical administration of acitretin may lessen the risk of systemic toxicity while increasing local bioavailability in the skin. The effects of topical acitretin on reconstructed human epidermis (RHE) and Rhino mice were investigated and compared to those of currently marketed topical retinoids: tretinoin and tazarotene. In acitretin-treated RHE cultures, there was a reduction in keratohyalin granules and filaggrin expression in the stratum granulosum, a loss of keratin 10 expression in the stratum spinosum, and an increase in keratin 19 expression in all viable cell layers. All retinoids showed similar signs of activity in RHE cultures. Furthermore, the release of pro-inflammatory cytokines IL-1alpha and IL-8 in RHE cultures was less pronounced with acitretin compared to tretinoin- and tazarotene-containing formulations, suggesting that acitretin may be less irritating. In Rhino mice, acitretin induced a local, dose-dependent reduction in utricle diameter after seven daily dermal doses. A similar effect was observed in tretinoin- and tazarotene-treated mice. Our data suggest that topical application of acitretin may have a therapeutic benefit in the local management of keratinization disorders.
Collapse
Affiliation(s)
- Edward Hsia
- Center for Skin Biology, Stiefel Laboratories Inc., Palo Alto, California 94304, USA
| | | | | | | | | |
Collapse
|
23
|
Klimowicz A, Farfał S, Bielecka-Grzela S. Evaluation of skin penetration of topically applied drugs in humans by cutaneous microdialysis: acyclovir vs. salicylic acid. J Clin Pharm Ther 2007; 32:143-8. [PMID: 17381664 DOI: 10.1111/j.1365-2710.2007.00803.x] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
BACKGROUND AND OBJECTIVE Cutaneous drug application is used for both local drug therapy and systemic treatment. For both types of treatment, the drug concentration profile in, and transport across, the skin is important. To evaluate skin penetration of topically-applied drugs we recently used cutaneous microdialysis. The aim of this study was the use of this method for studying acyclovir and salicylic acid. METHOD Five per cent acyclovir cream was applied on intact and tape-stripped skin of healthy volunteers and 5% salicylic acid ointment-onto intact skin of other volunteers. Microdialysis probes with 2 kDa molecular weight cut-off were inserted intradermally and were perfused with Ringer solution. Drug concentrations were measured by high-performance liquid chromatography. RESULTS Following topical application of 5% acyclovir cream onto intact skin of eight healthy volunteers, no drug was determinable in the skin (cutaneous microdialysate) in any of the subjects studied. After partial removal of the stratum corneum the penetration of this drug into skin increased markedly. The mean maximum skin concentration was about 2 x 5 micromol/L after 2 x 4 +/- 0 x 7 h. Topically applied salicylic acid penetrated intact skin with a maximum concentration in the cutaneous microdialysate of 7 x 57 +/- 3 x 90 micromol/L after 5 x 3 +/- 0 x 4 h. CONCLUSION Cutaneous microdialysis is a valuable method for estimating skin concentration of topically-applied drug. It allows evaluation after application to a small skin area, of about 2 cm(2), thereby reducing the risk of systemic toxicity. The method may be helpful for evaluating the influence of skin condition on the transport process.
Collapse
Affiliation(s)
- A Klimowicz
- Division of Dermatopharmacotherapy, Department of Dermatology and Venereology, Pomeranian Medical University, Szczecin, Poland.
| | | | | |
Collapse
|
24
|
Loftsson T, Sigurđardóttir AM, ólafsson JH. Improved acitretin delivery through hairless mouse skin by cyclodextrin complexation. Int J Pharm 1995. [DOI: 10.1016/0378-5173(94)00302-l] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
25
|
Laugier JP, Surber C, Bun H, Geiger JM, Wilhelm KP, Durand A, Maibach HI. Determination of acitretin in the skin, in the suction blister, and in plasma of human volunteers after multiple oral dosing. J Pharm Sci 1994; 83:623-8. [PMID: 8071808 DOI: 10.1002/jps.2600830505] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
Several HPLC methods for quantification of acitretin and its 13-cis isomer in biological fluids have been described. Only limited data are available on determination of this drug in skin samples. Our objective was to improve the sensitivity and selectivity of existing methods to measure drug in small skin samples from humans treated with acitretin. With a new optimized mobile phase [methanol: acetonitrile (7:3, v/v), purified water with 1.5% (v/v) acetic acid, mixed in a 85:15 ratio (v/v)] and a new internal standard (arotinoid ethyl sulfone), a limit of quantification of 1 ng/g tissue was reached. Nine male volunteers were given an oral daily dose of 50 mg acitretin for up to 28 days. Blood and skin samples (punch and shave biopsies, suction blister skin, and fluid) were taken at various time points during and after treatment. Drug concentration and metabolism in plasma and skin samples appeared to be linked in that the trans-isomer concentration was always higher than the cis-isomer concentration during dosing and 3 h after the last dose. However, 7 and 14 days after the last dose in plasma and in all tissue samples (except the shave biopsy), the all-trans-acitretin concentration rapidly decreased and approached the detection limit. In the shave biopsy, the all-trans-acitretin concentration remained higher than the 13-cis-acitretin concentration. Furthermore, the elimination of two isomers from the shave biopsy was delayed.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- J P Laugier
- Laboratoire Hospitalo-Universitaire de Pharmcocinetique et Toxicocinetique, Marseille, France
| | | | | | | | | | | | | |
Collapse
|